论文部分内容阅读
目的:探讨匹多莫德联合孟鲁司特钠治疗支气管哮喘的疗效及对患者炎性因子水平、免疫功能的影响。方法:收集诸暨市人民医院2019年2月至2020年2月收治的支气管哮喘患者102例为研究对象，按随机数字表法分为观察组、对照组各51例。两组在常规治疗的基础上，对照组给予孟鲁司特钠治疗，观察组联合匹多莫德治疗。观察比较两组患者的临床疗效、肺功能指标、炎性因子、T淋巴细胞亚群、不良反应发生率等。结果:观察组总有效率为90.20%(46/51)，高于对照组的74.51%(38/51)(χn 2＝4.317，n P＝0.038)；治疗后观察组患者第一秒用力呼气量(FEVn 1)、用力肺活量(FVC)、最大呼气流速(PEF)分别为(82.89±6.94)%、(3.89±0.45)L、(3.49±0.49)L/s，均高于对照组的(77.89±6.79)%、(3.58±0.43)L、(3.21±0.45)L/s(n t＝7.370、5.753、4.239，均n P<0.05)；治疗后观察组患者的炎性因子指标包括血清降钙素原(PCT)、白细胞介素6(IL-6)、C反应蛋白(CRP)，分别为(1.45±0.49)μg/L、(9.87±2.65)mg/L、(5.79±1.48)mg/L，低于对照组的(1.79±0.55)μg/L、(12.34±2.97)mg/L、(7.23±1.68)mg/L(n t＝4.624、6.542、8.090，均n P<0.05)；治疗后观察组患者的CDn 3＋、CDn 4＋、CDn 4＋/CDn 8＋均为(53.43±5.43)%、(46.34±5.31)%、(1.54±0.23)，高于对照组的(48.09±5.17)%、(41.89±5.15)%、(1.26±0.22)，而CDn 8＋为(30.65±3.54)%，低于对照组的(33.72±3.69)%，两组差异均有统计学意义(n t＝3.901、4.080、4.072、5.967，均n P<0.05)；治疗期间观察组、对照组不良反应发生率分别为15.69%(8/51)、9.80%(5/51)，组间差异无统计学意义(χn 2＝0.793，n P＝0.373)。n 结论:匹多莫德联合孟鲁司特钠对支气管哮喘的治疗效果显著，能够改善患者的肺功能，降低炎性因子水平，提高机体免疫功能，安全性良好。“,”Objective:To study the effect of pidotimod combined with montelukast sodium in the treatment of patients with asthma, and its influence on the levels of inflammatory factors and immune function.Methods:From February 2019 to February 2020, 102 patients with bronchial asthma admitted to Zhuji People's Hospital were randomly divided into the observation group and the control group, with 51 cases in each group.The control group was treated with montelukast sodium, and the observation group was given pidotimod combined with montelukast sodium.The clinical effect, lung function index, inflammatory factors, T lymphocyte subsets and the incidence of adverse reactions were compared between the two groups.Results:The total effective rate of the observation group was 90.20%(46/51), which was higher than that of the control group [74.51%(38/51)](χn 2=4.317, n P=0.038). After treatment, FEVn 1, FVC, PEF in the observation group were (82.89±6.94)%, (3.89±0.45)L, (3.49±0.49)L/s, respectively, which were higher than those in the control group [(77.89±6.79)%, (3.58±0.43)L, (3.21±0.45)L/s] (n t=7.370, 5.753, 4.239, all n P<0.05). After treatment, the serum levels of procalcitonin (PCT), interleukin-6 (IL-6), C-reactive protein (CRP) in the observation group were (1.45±0.49)μg/L, (9.87±2.65)mg/L, (5.79±1.48)mg/L, respectively, which were lower than those in the control group [(1.79±0.55)μg/L, (12.34±2.97)mg/L, (7.23±1.68)mg/L] (n t=4.624, 6.542, 8.090, all n P<0.05). After treatment, the CDn 3+ , CDn 4+ , CDn 4+ /CDn 8+ in the observation group were (53.43±5.43)%, (46.34±5.31)%, (1.54±0.23), respectively, which were higher than those in the control group [(48.09±5.17)%, (41.89±5.15)%, (1.26±0.22)], while the CDn 8+ in the observation group[(30.65±3.54)%] was lower than that in the control group[(33.72±3.69)%], the differences were statistically significant (n t=3.901, 4.080, 4.072, 5.967, all n P<0.05). During the treatment period, the incidences of adverse reactions in the observation group and the control group were 15.69%(8/51) and 9.80%(5/51), respectively, there was no statistically significant difference between the two groups (χn 2=0.793, n P=0.373).n Conclusion:Pidotimod combined with montelukast sodium has significant therapeutic effect on bronchial asthma.It can improve the pulmonary function, reduce the levels of inflammatory factors, improve the immune function of the body, and has good therapeutic safety.It has a high clinical application value.